Souhaitez-vous accéder aux communiqués récents ?

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN...

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN...

Ottawa, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The next-generation bispecific antibody market is rapidly advancing on a global scale, with expectations of accumulating hundreds of millions in revenue...

Company addresses looming government shutdown, highlighting resilient operations, no expected impact on SEC filings, and continued growth.

Dublin, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The "Artificial Intelligence In Pharmaceutical Market Report by Technology, Offering, Application, Deployment Mode, Countries and Company Analysis,...

REYKJAVIK, Iceland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...

REYKJAVIK, ICELAND (September 22, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today...

Q4 GAAP revenues of $596.9 million, up 6.2% from Q4 2024. For fiscal 2025, GAAP revenues were $2,321.7 million, up 5.4% year over year.Organic ASV was $2,370.9 million at August 31, 2025, up 5.7% year...

MATAWAN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Hovnanian Enterprises, Inc. (NYSE: HOV) (the “Company”) announced today that its wholly owned subsidiary, K. Hovnanian Enterprises, Inc. (“K....

MATAWAN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Hovnanian Enterprises, Inc. (NYSE: HOV) (the “Company”) announced today that its wholly owned subsidiary, K. Hovnanian Enterprises, Inc. (“K....